Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/29/2025

Tirzepatide for Class 1 Obesity Management

Medical Necessity Assessment

  • Class 1 obesity (BMI 30-34.9 kg/m²) is a chronic disease that warrants pharmacological intervention when lifestyle modifications alone have been insufficient, as stated by the American Gastroenterological Association 1, 2
  • FDA-approved weight loss medications, such as those recommended by the American Diabetes Association, are indicated for patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related comorbidity 3, 2
  • The American Gastroenterological Association suggests that weight reduction medications should be considered as adjuncts to lifestyle interventions in patients who have been unable to lose and maintain weight with diet and exercise alone 5, 3

Dosing and Monitoring Considerations

  • The American College of Gastroenterology recommends that tirzepatide should be initiated at 2.5mg weekly with gradual dose escalation based on efficacy and tolerability 4, 2
  • Efficacy and safety should be assessed at least monthly for the first 3 months and then at least every 3 months, as advised by the American Gastroenterological Association 2
  • The American Diabetes Association recommends that treatment should be discontinued if 5% weight loss is not achieved after 12 weeks at the maintenance dose 3, 6

Expected Benefits Beyond Weight Loss

  • The European Society of Cardiology notes that tirzepatide improves multiple cardiometabolic risk factors including blood pressure, lipid profiles, and waist circumference 7

Common Side Effects and Management

  • The American College of Gastroenterology reports that most common adverse events are gastrointestinal in nature (nausea, vomiting, diarrhea) and that slow titration can minimize gastrointestinal side effects 4